Top

Published in:

01-10-2019 | Editorial

The HCV Treatment Cascade: Race Is a Factor to Consider

Authors: Maya Balakrishnan, MD, MPH, Fasiha Kanwal, MD, MSHS

Published in: Journal of General Internal Medicine | Issue 10/2019

Excerpt

Chronic hepatitis C is the most common blood-borne viral infection in the USA and a leading cause of chronic liver disease, liver failure, and hepatocellular carcinoma (HCC). The complications of HCV infection are preventable. Antiviral treatment with sustained virological response (SVR) is associated with a 71–76% reduction in HCC risk¹ and a 74% reduction in risk of death compared to ongoing active infection.² …

Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017;153(4):996–1005.e1.CrossRef

Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology (Baltimore, Md). 2017.

Yehia BR, Schranz AJ, Umscheid CA, Lo Re V, 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PloS One. 2014;9(7):e101554.CrossRef

Brady JE, Vellozzi C, Hariri S, Kruger DL, Nerenz DR, Brown KA, et al. Hepatitis C care cascade among persons born 1945-1965: 3 medical centers. Am J Manag Care. 2018;24(9):421–7.

Kim NJ, Locke CJ, Park H, Magee C, Bacchetti P, Khalili M. Race and Hepatitis C Care Continuum in an Underserved Birth Cohort. J Gen Intern Med. https://doi.org/10.1007/s11606-018-4649-6.CrossRef

Kasting ML, Giuliano AR, Reich RR, Roetzheim RG, Nelson DR, Shenkman E, et al. Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2018;27(4):503–13.

Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis c antibody in u.s. primary care settings. Ann Intern Med. 2012;156(4):263–70.CrossRef

Lin M, Kramer J, White D, Cao Y, Tavakoli-Tabasi S, Madu S, et al. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017;46(10):992–1000.CrossRef

Nili M, Luo L, Feng X, Chang J, Tan X. Disparities in hepatitis C virus infection screening among Baby Boomers in the United States. Am J Infect Control. 2018;46(12):1341–7.CrossRef

10.

Backus LI, Belperio PS, Loomis TP, Mole LA. Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care. Am J Public Health. 2014;104 Suppl 4:S555–61.CrossRef

11.

Chhatwal J, Chen Q, Ayer T, Bethea ED, Kanwal F, Kowdley KV, et al. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther. 2018;47(7):1023–31.CrossRef

12.

Turner BJ, Wang CP, Melhado TV, Bobadilla R, Jain MK, Singal AG. Significant Increase in Risk of Fibrosis or Cirrhosis at Time of HCV Diagnosis for Hispanics With Diabetes and Obesity Compared with Other Ethnic Groups. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2018.

13.

El-Serag HB, Kramer J, Duan Z, Kanwal F. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014;109(9):1427–35.CrossRef

14.

Eckman MH, Ward JW, Sherman KE. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2018.

Title: The HCV Treatment Cascade: Race Is a Factor to Consider
Authors: Maya Balakrishnan, MD, MPH
Fasiha Kanwal, MD, MSHS
Publication date: 01-10-2019
Publisher: Springer International Publishing
Published in: Journal of General Internal Medicine / Issue 10/2019
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-019-04962-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The HCV Treatment Cascade: Race Is a Factor to Consider

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2019

Improving Network Science in Health Services Research

Hospitalist-Operated Compression Ultrasonography: a Point-of-Care Ultrasound Study (HOCUS-POCUS)

Understanding the Mentoring Environment Through Thematic Analysis of the Learning Environment in Medical Education: a Systematic Review

Effect of Electronic Prescribing Strategies on Medication Error and Harm in Hospital: a Systematic Review and Meta-analysis

Understanding Long-Term Cancer Survivors’ Preferences for Ongoing Medical Care

Skin Bends: a Cutaneous Manifestation of Decompression Sickness

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page